Characterisation of five factor XI mutations

Michael J. Mitchell; Letian Dai; John B. Clarke; Paula H. B. Bolton-Maggs; Geoffrey F. Savidge; Anwar Alhaq

doi:10.1160/TH06-12-0704

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2007; 97(06): 884-889
DOI: 10.1160/TH06-12-0704

Blood Coagulation, Fibrinolysis and Cellular Haemostasis

Schattauer GmbH

Characterisation of five factor XI mutations

Michael J. Mitchell

¹Centre for Haemostasis and Thrombosis, Haemophilia Reference Centre, St. Thomas Hospital, London, UK

,

Letian Dai

¹Centre for Haemostasis and Thrombosis, Haemophilia Reference Centre, St. Thomas Hospital, London, UK

,

John B. Clarke

¹Centre for Haemostasis and Thrombosis, Haemophilia Reference Centre, St. Thomas Hospital, London, UK

,

Paula H. B. Bolton-Maggs

²Clinical Haematology, Manchester Royal Infirmary, Manchester, UK

,

Geoffrey F. Savidge

¹Centre for Haemostasis and Thrombosis, Haemophilia Reference Centre, St. Thomas Hospital, London, UK

,

Anwar Alhaq

¹Centre for Haemostasis and Thrombosis, Haemophilia Reference Centre, St. Thomas Hospital, London, UK

› Author Affiliations

Abstract

Summary

A large scale factor XI (FXI) mutation screening program identified a number of novel candidate mutations and previously reported mutations and polymorphisms. Five potential missense mutations were selected for further study; these included two novel missense mutations – Met-18Ile (p.Met1Ile) and Met102Thr (p.Met120Thr), two previously reported missense mutations – Tyr133Ser (Tyr151Ser) and Thr575Met (Thr593Met), and one amino acid substitution previously reported as a polymorphism – Arg378Cys (Arg396Cys). The substitutions were recreated by the site-directed mutagenesis of a FXI cDNA and stably expressed in a BHK-570 cell line. Subsequent analysis of both the conditioned media and cell lysates showed that three of the substitutions, Met-18Ile, Met102Thr andTyr133Ser, prevented secretion of the mutated protein from the transfected cell line, resulting in a cross-reactive material negative (CRM-) phenotype. The remaining two mutants, Thr575Met and Arg378Cys, secreted significant levels of FXI into the conditioned media; however, these mutant FXIs were shown to have negligible factor IX activation activity in an APTT based assay. These results confirmed all five of the missense mutations as being causative of factor XI deficiency, despite one having been previously reported as a polymorphism (Arg378Cys) and one (Tyr133Ser) as a mild mutation – FXI:C 38 U/dl in a homozygous patient.

Keywords

Factor XI - site-directed mutagenesis - expression studies

Full Text

References

References
1 Walsh PN, Ahmad SS. Proteases in blood clotting. Essays Biochem 2002; 38: 95-111.
2 Walsh PN. Roles of platelets and factor XI in the initiation of blood coagulation by thrombin. Thromb Haemost 2001; 86: 75-82.
3 Baird TR, Walsh PN. The interaction of factor XIa with activated platelets but not endothelial cells promotes the activation of factor IX in the consolidation phase of blood coagulation. J Biol Chem 2002; 277: 38462-38467.
4 Kato A, Asakai R, Davie EW. et al. Factor XI gene (F11) is located on the distal end of the long arm of human chromosome 4. Cytogenet Cell Genet 1989; 52: 77-78.
5 Asakai R, Davie EW, Chung DW. Organization of the gene for human factor XI. Biochemistry 1987; 26: 7221-7228.
6 Asakai R, Chung DW, Ratnoff OD. et al. Factor XI (plasma thromboplastin antecedent) deficiency in Ashkenazi Jews is a bleeding disorder that can result from three types of point mutations. Proc Natl Acad Sci USA 1989; 86: 7667-7671.
7 Saunders RE, O'Connell NM, Lee CA. et al. Factor XI deficiency database: an interactive web database of mutations, phenotypes, and structural analysis tools. Hum Mutat 2005; 26: 192-198.
8 Kravtsov DV, Wu W, Meijers JC. et al. Dominant factor XI deficiency caused by mutations in the factor XI catalytic domain. Blood 2004; 104: 128-134.
9 Kravtsov DV, Monahan PE, Gailani D. A classification system for cross-reactive material-negative factor XI deficiency. Blood 2005; 105: 4671-4673.
10 Gailani D, Bolton-Maggs PHB, Blinder M. et al. Amino acid substitutions in the factor XI catalytic domain associated with factor XI deficiency. Thromb Haemost. 2001. (Suppl): Abstract.
11 Alhaq A, Mitchell M, Sethi M. et al. Identification of a novel mutation in a non-Jewish factor XI deficient kindred. Br J Haematol 1999; 104: 44-49.
12 Mitchell M, Harrington P, Cutler J. et al. Eighteen unrelated patients with factor XI deficiency, four novel mutations and a 100% detection rate by denaturing high-performance liquid chromatography. Br J Haematol 2003; 121: 500-502.
13 Tarumi T, Kravtsov DV, Zhao M. et al. Cloning and characterization of the human factor XI gene promoter: transcription factor hepatocyte nuclear factor 4alpha (HNF-4alpha ) is required for hepatocyte-specific expression of factor XI. J Biol Chem 2002; 277: 18510-18516.
14 McVey JH, Lal K, Imanaka Y. et al. Characterisation of blood coagulation factor XI T475I. Thromb Haemost 2005; 93: 1082-1088.
15 Zadra G, Asselta R, Malcovati M. et al. Molecular genetic analysis of severe coagulation factor XI deficiency in six Italian patients. Haematologica 2004; 89: 1332-1340.
16 Zivelin A, Bauduer F, Ducout L. et al. Factor XI deficiency in French Basques is caused p by an ancestral Cys38Arg mutation in the factor XI gene. Blood 2002; 99: 2448-2454.
17 Hill M, McLeod F, Franks H. et al. Genetic analysis in FXI deficiency: six novel mutations and the use of a polymerase chain reaction-based test to define a whole gene deletion. Br J Haematol 2005; 129: 825-829.
18 RajBhandary UL. More surprises in translation: initiation without the initiator tRNA. Proc Natl Acad Sci USA 2000; 97: 1325-1327.
19 Drabkin HJ, RajBhandary UL. Initiation of protein synthesis in mammalian cells with codons other than AUG and amino acids other than methionine. Mol Cell Biol 1998; 18: 5140-5147.
20 Peabody DS. Translation initiation at non-AUG triplets in mammalian cells. J Biol Chem 1989; 264: 5031-5035.
21 Sasaki J, Nakashima N. Methionine-independent initiation of translation in the capsid protein of an insect RNA virus. Proc Natl Acad Sci USA 2000; 97: 1512-1515.
22 Papagrigoriou E, McEwan PA, Walsh PN. et al. Crystal structure of the factor XI zymogen reveals a pathway for transactivation. Nat Struct Mol Biol 2006; 13: 557-558.
23 Cheng Q, Sun MF, Kravtsov DV. et al. Factor XI apple domains and protein dimerization. J Thromb Haemost 2003; 1: 2340-2347.
24 Bolton-Maggs PBR, Mountford R, Gailani D. Eleven novel mutations in non-Jewish factor XI deficient kindreds detected by SSCP with heteroduplex analysis followed by sequencing. J Thromb Haemost 2003; 1 (Suppl): Abstract P1687.
25 Mitchell M, Mountford R, Butler R. et al. Spectrum of factor XI (F11) mutations in the UK population--116 index cases and 140 mutations. Hum Mutat 2006; 27: 829.
26 Germanos-Haddad M, De Moerloose P, Neerman-Arbez M. Molecular analysis of factor XI deficeincy in 8 Lebanese families: identification of two novel mutations. J Thromb Haemost 2003; 1 (Suppl): Abstract P1207.
27 Bolton-Maggs PH, Peretz H, Butler R. et al. A common ancestral mutation (C128X) occurring in 11 non- Jewish families from the UK with factor XI deficiency. J Thromb Haemost 2004; 2: 918-924.